Darzalex SC (Daratumumab)
daratumumab 1.8 g/15 mL injection, 15 mL vial · INJECTION · PBS code 13199Q
AUTHORITY_REQUIREDWhat it costs
AU$6659.77 PBS-determined price per 1 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2023-01-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Newly diagnosed systemic light chain amyloidosis
Continuing treatment from week 25 onwards (administered once every four weeks)
Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
Must be treated by a haematologist (this does not exclude treatment via a multidisciplinary team, but the PBS authority application must be sought by the treating haematologist); AND
Patient must be undergoing continuing treatment that does not extend treatment duration beyond whichever comes first: (i) disease progression, (ii) 96 cumulative weeks from the first administered dose, once in a lifetime.
Sponsor: Janssen-Cilag Pty Ltd ABN 47 000 129 975
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.